Evidence on the efficacy of systemic therapy for unresectable NAM is scarce, but immune checkpoint inhibitors and BRAF/MEK inhibitors have superseded conventional cytotoxic chemotherapy. The gene discussed is MAP2K7; the disease is Bailey-Bloch congenital myopathy.